StockData
Bicara Therapeutics Inc. logo

Bicara Therapeutics Inc. (BCAX) stock

BCAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$9.75−0.27 (-2.69%)

Close on Nov 16, 2026Market cap $645.19MP/E –Yield –

Bicara Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Bicara Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2025 was $112.00M, up 106.6% year over year. For fiscal 2024 it was $63.60M, up 107.8% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2024Dec 31, 2024$63.60M+107.8%
FY2023Dec 31, 2023$30.60M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2025Sep 30, 2025$33.00M+107.5%
Q2 FY2025Jun 30, 2025$24.80M+57.0%
Q1 FY2025Mar 31, 2025$34.30M+185.8%
Q4 FY2024Dec 31, 2024$19.90M+89.5%
Q3 FY2024Sep 30, 2024$15.90M+130.4%
Q2 FY2024Jun 30, 2024$15.80M–
Q1 FY2024Mar 31, 2024$12.00M–
Q4 FY2023Dec 31, 2023$10.50M–
Q3 FY2023Sep 30, 2023$6.90M–

More Bicara Therapeutics figures

See a number that looks wrong?